CN111670046B - 疫苗的t细胞增强剂 - Google Patents

疫苗的t细胞增强剂 Download PDF

Info

Publication number
CN111670046B
CN111670046B CN201880071581.4A CN201880071581A CN111670046B CN 111670046 B CN111670046 B CN 111670046B CN 201880071581 A CN201880071581 A CN 201880071581A CN 111670046 B CN111670046 B CN 111670046B
Authority
CN
China
Prior art keywords
antigen
inv
antigens
fragment
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880071581.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN111670046A (zh
Inventor
阿尔弗雷多·尼科西亚
埃莉萨·斯卡尔塞利
安东内拉·福尔戈里
阿明·拉姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nouscom AG
Original Assignee
Nouscom AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nouscom AG filed Critical Nouscom AG
Publication of CN111670046A publication Critical patent/CN111670046A/zh
Application granted granted Critical
Publication of CN111670046B publication Critical patent/CN111670046B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201880071581.4A 2017-11-03 2018-11-02 疫苗的t细胞增强剂 Active CN111670046B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17200036 2017-11-03
EP17200036.6 2017-11-03
EP17211235.1 2017-12-29
EP17211235 2017-12-29
PCT/EP2018/080027 WO2019086615A1 (en) 2017-11-03 2018-11-02 Vaccine t cell enhancer

Publications (2)

Publication Number Publication Date
CN111670046A CN111670046A (zh) 2020-09-15
CN111670046B true CN111670046B (zh) 2024-11-08

Family

ID=64332267

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880071581.4A Active CN111670046B (zh) 2017-11-03 2018-11-02 疫苗的t细胞增强剂

Country Status (12)

Country Link
US (1) US11912743B2 (https=)
EP (1) EP3703744A1 (https=)
JP (2) JP7386537B2 (https=)
KR (1) KR102747530B1 (https=)
CN (1) CN111670046B (https=)
AU (1) AU2018358019B2 (https=)
BR (1) BR112020008308A2 (https=)
CA (1) CA3078692A1 (https=)
IL (1) IL274409B2 (https=)
MX (1) MX2020004552A (https=)
SG (1) SG11202003799RA (https=)
WO (1) WO2019086615A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210081325A (ko) * 2018-10-19 2021-07-01 노우스콤 아게 경골어류 불변 사슬 암 백신
SG11202103243PA (en) * 2018-11-15 2021-04-29 Nouscom Ag Selection of cancer mutations for generation of a personalized cancer vaccine
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
KR20220115569A (ko) 2019-11-18 2022-08-17 얀센 바이오테크 인코포레이티드 돌연변이 calr 및 jak2에 기반한 백신 및 이의 용도
EP4135757A1 (en) * 2020-04-13 2023-02-22 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4448001A4 (en) * 2021-12-16 2025-12-03 Janssen Biotech Inc PROSTATE CANCER VACCINES AND THEIR USES

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015082922A1 (en) * 2013-12-04 2015-06-11 Isis Innovation Limited Molecular adjuvant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE449105T1 (de) 2004-01-23 2009-12-15 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
HUE045093T2 (hu) * 2008-11-21 2019-12-30 Kobenhavns Univ University Of Copenhagen Immunválasz kiváltása
EP2391638B1 (en) 2009-02-02 2018-06-27 GlaxoSmithKline Biologicals SA Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2012141984A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2016013672A1 (ja) 2014-07-25 2016-01-28 国立研究開発法人理化学研究所 メモリーインバリアントｎｋｔ細胞マーカー
JP7298926B2 (ja) * 2017-07-12 2023-06-27 ノイスコム アーゲー 癌の治療のためのネオアンチゲンワクチン組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015082922A1 (en) * 2013-12-04 2015-06-11 Isis Innovation Limited Molecular adjuvant

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Enhanced vaccine-induced CD8+ T cell responses to malaria antigen ME-TRAP by fusion to MHC class ii invariant chain;SPENCER AJ等;《PLOS ONE》;20140601;全文 *
Fusion of HCV nonstructural antigen to MHC class II-associated invariant chain enhances T-cel1 responses induced by vectored vaccines in nonhuman primates;CAPONE STEFANIA等;《MOLECULAR THERAPY 》;20140501;全文 *

Also Published As

Publication number Publication date
JP7485422B2 (ja) 2024-05-16
RU2020115109A (ru) 2021-12-03
AU2018358019A1 (en) 2020-04-23
US20210363201A1 (en) 2021-11-25
WO2019086615A1 (en) 2019-05-09
AU2018358019B2 (en) 2023-05-11
IL274409B1 (en) 2023-07-01
CN111670046A (zh) 2020-09-15
RU2020115109A3 (https=) 2021-12-03
JP2023089103A (ja) 2023-06-27
KR20200076696A (ko) 2020-06-29
EP3703744A1 (en) 2020-09-09
SG11202003799RA (en) 2020-05-28
US11912743B2 (en) 2024-02-27
BR112020008308A2 (pt) 2020-11-17
JP7386537B2 (ja) 2023-11-27
KR102747530B1 (ko) 2024-12-27
IL274409B2 (en) 2023-11-01
NZ763337A (en) 2025-02-28
IL274409A (en) 2020-06-30
JP2021502076A (ja) 2021-01-28
MX2020004552A (es) 2020-10-07
CA3078692A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
CN111670046B (zh) 疫苗的t细胞增强剂
CN112955177B (zh) 真骨鱼恒定链癌症疫苗
AU2018300051B2 (en) Neoantigen vaccine composition for treatment of cancer
CN113227121A (zh) 通过特异性结合至靶细胞具有增强的多种免疫功能的嵌合抗原及其用途
RU2794196C2 (ru) Усилитель t-клеточного ответа на вакцину
CA3109541C (en) Teleost invariant chain cancer vaccine
RU2808567C2 (ru) Противораковая вакцина с инвариантной цепью из костистых рыб
RU2782261C2 (ru) Вакцинная композиция для лечения рака
NZ759944B2 (en) Neoantigen vaccine composition for treatment of cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment